Report Description

Global gastric cancer therapeutics market is anticipated to show a robust growth in the upcoming five years, 2023-2027. The market is expected to show an impressive growth of CAGR in the forecast period owing to the rising cases of cancer and limited number of effective drugs. Moreover, the research and development that is consistently being conducted by various research institutes and labs is expected to drive the growth of global gastric cancer therapeutics market in the next five years.

Also, the growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors, etc. are also driving the growth of the global gastric cancer therapeutics market. Treatment for gastric cancer basically depends upon the stage of cancer. Various treatment methods are available such as surgery, targeted drugs, chemotherapy, etc. The factors that propel the growth of the global gastric cancer therapeutics market include innovations in treatment, a growing number of cancer treatment centers, increasing research and development activities, and combination therapies.

The global gastric cancer therapeutics market is segmented on the basis of therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitive landscape, and regional distribution. Based on therapy type the market is further bifurcated into Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery.

Targeted therapy is anticipated to hold the largest share of the market in the forecast period. The growth can be attributed to the delivery of advanced technological approaches like stem cell therapy, etc. Chemotherapy is also anticipated to hold the significant amount of market share owing to its efficiency in controlling the growth of the cancerous cells and thus have proved to be quite beneficial.

Some of the major competitors in the market are Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Array Biopharma Inc., AstraZeneca PLC, Ipsen Biopharmaceuticals Ltd., Taiho Oncology Inc., Galena Biopharma Inc., among others.

Objective of the Study:

  • To analyze the historical growth of the market size of global gastric cancer therapeutics market from 2017 to 2021.
  • To estimate and forecast the market size of global gastric cancer therapeutics market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global gastric cancer therapeutics market based on therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitional landscape, and regional distribution.
  • To identify dominant region or segment in the global gastric cancer therapeutics market.
  • To identify drivers and challenges for global gastric cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global gastric cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in global gastric cancer therapeutics market.
  • To identify key sustainable strategies adopted by market players in global gastric cancer therapeutics market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global gastric cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of gastric cancer therapeutics and other stakeholders
  • Organizations, forums, and alliances related to gastric cancer therapeutics market  
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as vendors, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Attribute

Details

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million and CAGR for 2017-2021 and 2022-2027

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

  • Therapy Type
  • Disease Indication
  • Molecule Type
  • Line of Therapy
  • Mode of Action
  • Route of Administration
  • End User
  • Distribution Channel

Regional Scope

North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa

Country Scope

United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa;

Key Companies Profiled

Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Array Biopharma Inc., AstraZeneca PLC, Ipsen Biopharmaceuticals Ltd., Taiho Oncology Inc., Galena Biopharma Inc..

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global gastric cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Gastric Cancer Therapeutics Market, By Therapy Type:
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Radiation Therapy
    • Surgery
  • Global Gastric Cancer Therapeutics Market, By Disease Indication:
    • Gastric Adenocarcinoma
    • Gastrointestinal Stromal Tumor (GIST)
    • Gastric Neuroendocrine Tumors (gNET)
  • Global Gastric Cancer Therapeutics Market, By Molecule Type:
    • Small Molecule
    • Biologics
  • Global Gastric Cancer Therapeutics Market, By Line of Therapy:
    • Neoadjuvant and Adjuvant
    • First Line Therapy
    • Second Line Therapy
  • Global Gastric Cancer Therapeutics Market, By Mode of Action:
    • Programmed Cell Death Protein 1 (PD-1) Inhibitors
    • Human Epidermal Growth Factor Receptor (HER2) Antagonists
    • Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
    • Others
      • Microtubule Inhibitors
      • Kinase Inhibitors
  • Global Gastric Cancer Therapeutics Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Gastric Cancer Therapeutics Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Global Gastric Cancer Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Gastric Cancer Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Gastric Cancer Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Gastric Cancer Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Gastric Cancer Therapeutics Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Gastric Cancer Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)

6.2.2.     By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST), Gastric Neuroendocrine Tumors (gNET))

6.2.3.     By Molecule Type (Small Molecule, Biologics)

6.2.4.     By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy)

6.2.5.     By Mode of Action (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists, Others (Microtubule Inhibitors, Kinase Inhibitors))

6.2.6.     By Route of Administration (Oral vs. Parenteral)

6.2.7.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.8.     By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

6.2.9.     By Company (2021)

6.2.10.  By Region

6.3.  Product Market Map

7.    Asia-Pacific Gastric Cancer Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapy Type

7.2.2.     By Disease Indication

7.2.3.     By Molecule Type

7.2.4.     By Line of Therapy

7.2.5.     By Mode of Action

7.2.6.     By Route of Administration

7.2.7.     By End User

7.2.8.     By Distribution Channel

7.2.9.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Gastric Cancer Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapy Type

7.3.1.2.2.             By Disease Indication

7.3.1.2.3.             By Molecule Type

7.3.1.2.4.             By Line of Therapy

7.3.1.2.5.             By Mode of Action

7.3.1.2.6.             By Route of Administration

7.3.1.2.7.             By End User

7.3.1.2.8.             By Distribution Channel

7.3.2.     India Gastric Cancer Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapy Type

7.3.2.2.2.             By Disease Indication

7.3.2.2.3.             By Molecule Type

7.3.2.2.4.             By Line of Therapy

7.3.2.2.5.             By Mode of Action

7.3.2.2.6.             By Route of Administration

7.3.2.2.7.             By End User

7.3.2.2.8.             By Distribution Channel

7.3.3.     Japan Gastric Cancer Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapy Type

7.3.3.2.2.             By Disease Indication

7.3.3.2.3.             By Molecule Type

7.3.3.2.4.             By Line of Therapy

7.3.3.2.5.             By Mode of Action

7.3.3.2.6.             By Route of Administration

7.3.3.2.7.             By End User

7.3.3.2.8.             By Distribution Channel

7.3.4.     South Korea Gastric Cancer Therapeutics Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Therapy Type

7.3.4.2.2.             By Disease Indication

7.3.4.2.3.             By Molecule Type

7.3.4.2.4.             By Line of Therapy

7.3.4.2.5.             By Mode of Action

7.3.4.2.6.             By Route of Administration

7.3.4.2.7.             By End User

7.3.4.2.8.             By Distribution Channel

7.3.5.     Australia Gastric Cancer Therapeutics Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Therapy Type

7.3.5.2.2.             By Disease Indication

7.3.5.2.3.             By Molecule Type

7.3.5.2.4.             By Line of Therapy

7.3.5.2.5.             By Mode of Action

7.3.5.2.6.             By Route of Administration

7.3.5.2.7.             By End User

7.3.5.2.8.             By Distribution Channel

8.    Europe Gastric Cancer Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapy Type

8.2.2.     By Disease Indication

8.2.3.     By Molecule Type

8.2.4.     By Line of Therapy

8.2.5.     By Mode of Action

8.2.6.     By Route of Administration

8.2.7.     By End User

8.2.8.     By Distribution Channel

8.2.9.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Gastric Cancer Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapy Type

8.3.1.2.2.             By Disease Indication

8.3.1.2.3.             By Molecule Type

8.3.1.2.4.             By Line of Therapy

8.3.1.2.5.             By Mode of Action

8.3.1.2.6.             By Route of Administration

8.3.1.2.7.             By End User

8.3.1.2.8.             By Distribution Channel

8.3.2.     Germany Gastric Cancer Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapy Type

8.3.2.2.2.             By Disease Indication

8.3.2.2.3.             By Molecule Type

8.3.2.2.4.             By Line of Therapy

8.3.2.2.5.             By Mode of Action

8.3.2.2.6.             By Route of Administration

8.3.2.2.7.             By End User

8.3.2.2.8.             By Distribution Channel

8.3.3.     United Kingdom Gastric Cancer Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapy Type

8.3.3.2.2.             By Disease Indication

8.3.3.2.3.             By Molecule Type

8.3.3.2.4.             By Line of Therapy

8.3.3.2.5.             By Mode of Action

8.3.3.2.6.             By Route of Administration

8.3.3.2.7.             By End User

8.3.3.2.8.             By Distribution Channel

8.3.4.     Italy Gastric Cancer Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapy Type

8.3.4.2.2.             By Disease Indication

8.3.4.2.3.             By Molecule Type

8.3.4.2.4.             By Line of Therapy

8.3.4.2.5.             By Mode of Action

8.3.4.2.6.             By Route of Administration

8.3.4.2.7.             By End User

8.3.4.2.8.             By Distribution Channel

8.3.5.     Spain Gastric Cancer Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapy Type

8.3.5.2.2.             By Disease Indication

8.3.5.2.3.             By Molecule Type

8.3.5.2.4.             By Line of Therapy

8.3.5.2.5.             By Mode of Action

8.3.5.2.6.             By Route of Administration

8.3.5.2.7.             By End User

8.3.5.2.8.             By Distribution Channel

9.    North America Gastric Cancer Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapy Type

9.2.2.     By Disease Indication

9.2.3.     By Molecule Type

9.2.4.     By Line of Therapy

9.2.5.     By Mode of Action

9.2.6.     By Route of Administration

9.2.7.     By End User

9.2.8.     By Distribution Channel

9.2.9.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Gastric Cancer Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapy Type

9.3.1.2.2.             By Disease Indication

9.3.1.2.3.             By Molecule Type

9.3.1.2.4.             By Line of Therapy

9.3.1.2.5.             By Mode of Action

9.3.1.2.6.             By Route of Administration

9.3.1.2.7.             By End User

9.3.1.2.8.             By Distribution Channel

9.3.2.     Mexico Gastric Cancer Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapy Type

9.3.2.2.2.             By Disease Indication

9.3.2.2.3.             By Molecule Type

9.3.2.2.4.             By Line of Therapy

9.3.2.2.5.             By Mode of Action

9.3.2.2.6.             By Route of Administration

9.3.2.2.7.             By End User

9.3.2.2.8.             By Distribution Channel

9.3.3.     Canada Gastric Cancer Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapy Type

9.3.3.2.2.             By Disease Indication

9.3.3.2.3.             By Molecule Type

9.3.3.2.4.             By Line of Therapy

9.3.3.2.5.             By Mode of Action

9.3.3.2.6.             By Route of Administration

9.3.3.2.7.             By End User

9.3.3.2.8.             By Distribution Channel

10.  South America Gastric Cancer Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapy Type

10.2.2.  By Disease Indication

10.2.3.  By Molecule Type

10.2.4.  By Line of Therapy

10.2.5.  By Mode of Action

10.2.6.  By Route of Administration

10.2.7.  By End User

10.2.8.  By Distribution Channel

10.2.9.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Gastric Cancer Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapy Type

10.3.1.2.2.           By Disease Indication

10.3.1.2.3.           By Molecule Type

10.3.1.2.4.           By Line of Therapy

10.3.1.2.5.           By Mode of Action

10.3.1.2.6.           By Route of Administration

10.3.1.2.7.           By End User

10.3.1.2.8.           By Distribution Channel

10.3.2.  Argentina Gastric Cancer Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapy Type

10.3.2.2.2.           By Disease Indication

10.3.2.2.3.           By Molecule Type

10.3.2.2.4.           By Line of Therapy

10.3.2.2.5.           By Mode of Action

10.3.2.2.6.           By Route of Administration

10.3.2.2.7.           By End User

10.3.2.2.8.           By Distribution Channel

10.3.3.  Colombia Gastric Cancer Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapy Type

10.3.3.2.2.           By Disease Indication

10.3.3.2.3.           By Molecule Type

10.3.3.2.4.           By Line of Therapy

10.3.3.2.5.           By Mode of Action

10.3.3.2.6.           By Route of Administration

10.3.3.2.7.           By End User

10.3.3.2.8.           By Distribution Channel

11.  Middle East and Africa Gastric Cancer Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Therapy Type

11.2.2.  By Disease Indication

11.2.3.  By Molecule Type

11.2.4.  By Line of Therapy

11.2.5.  By Mode of Action

11.2.6.  By Route of Administration

11.2.7.  By End User

11.2.8.  By Distribution Channel

11.2.9.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Gastric Cancer Therapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Therapy Type

11.3.1.2.2.           By Disease Indication

11.3.1.2.3.           By Molecule Type

11.3.1.2.4.           By Line of Therapy

11.3.1.2.5.           By Mode of Action

11.3.1.2.6.           By Route of Administration

11.3.1.2.7.           By End User

11.3.1.2.8.           By Distribution Channel

11.3.2.  Saudi Arabia Gastric Cancer Therapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Therapy Type

11.3.2.2.2.           By Disease Indication

11.3.2.2.3.           By Molecule Type

11.3.2.2.4.           By Line of Therapy

11.3.2.2.5.           By Mode of Action

11.3.2.2.6.           By Route of Administration

11.3.2.2.7.           By End User

11.3.2.2.8.           By Distribution Channel

11.3.3.  UAE Gastric Cancer Therapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Therapy Type

11.3.3.2.2.           By Disease Indication

11.3.3.2.3.           By Molecule Type

11.3.3.2.4.           By Line of Therapy

11.3.3.2.5.           By Mode of Action

11.3.3.2.6.           By Route of Administration

11.3.3.2.7.           By End User

11.3.3.2.8.           By Distribution Channel

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Clinical Trial Analysis

15.  Competitive Landscape

15.1.              Competition Outlook

15.2.              Players Profiled

15.2.1.  Bristol-Myers Squibb AB

15.2.2.  Celltrion Inc.

15.2.3.  Eli Lilly and Company

15.2.4.  Hoffmann-La Roche Ltd.

15.2.5.  GlaxoSmithKline PLC

15.2.6.  Imugene Limited

15.2.7.  Novartis AG

15.2.8.  Merck & Co. Inc.

15.2.9.  Otsuka Holdings Co. Ltd

15.2.10. Pfizer Inc.

15.2.11. Array Biopharma Inc.

15.2.12. AstraZeneca PLC

15.2.13. Ipsen Biopharmaceuticals Ltd.

15.2.14. Taiho Oncology Inc.

15.2.15. Galena Biopharma Inc.

16.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Rising cases of cancer, limited number of effective drugs, growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors, etc. are driving the growth of the global gastric cancer therapeutics market in the forecast years, 2023-2027.

down-arrow

Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, among others are leading the global gastric cancer therapeutics market in the forecast period, 2023-2027.

down-arrow

The global gastric cancer therapeutics market analysis was analyzed for the five historical years from 2017 to 2020. Keeping the base year 2020 as the margin, the estimation for the year 2022 was made and further market growth is predicted for the forecast years, 2023 to 2027.

down-arrow

New market players may invest actively in research and innovative product development. Also, advancing their existent technology according to evolving consumer preferences along with merger and acquisitions with the global giants can be viable strategic recommendations for the future brand establishments.

profile

Sakshi Bajaal

Business Consultant
Press Release

Gastric Cancer Therapeutics Market to Grow at an Impressive CAGR During the Forecast Period

Apr, 2021

Rising cases of stomach cancer to drive the growth of Global Gastric Cancer Therapeutics Market, in the forecast period, 2022-2026.